Adicet Bio
ACET
65 hedge funds and large institutions have $218M invested in Adicet Bio in 2021 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 18 increasing their positions, 15 reducing their positions, and 8 closing their positions.
150% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 8
23% more funds holding
Funds holding: 53 → 65 (+12)
20% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 15
0.13% more ownership
Funds ownership: 4.04% → 4.17% (+0.13%)
18% less capital invested
Capital invested by funds: $266M → $218M (-$48.1M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$9.49M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.22M |
| 3 |
State Street
Boston,
Massachusetts
|
+$3.06M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.53M |
| 5 |
6CM
683 Capital Management
New York
|
+$2.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$10.4M |
| 2 |
CCM
Consonance Capital Management
New York
|
-$2.44M |
| 3 |
JGC
J. Goldman & Co
New York
|
-$1.26M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$1.09M |
| 5 |
Millennium Management
New York
|
-$1.08M |
ACET Hedge Fund Activity: Q2 2021 in Review
65 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Adicet Bio (ACET) for Q2 2021, worth a combined $218M — down 18% from $266M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new ACET positions and 8 closed out — a net gain of 12 holders — while 18 added to existing stakes and 15 trimmed.
The largest buyer was BlackRock, adding an estimated $9.49M. The largest seller was VR Adviser, cutting an estimated $10.4M.
- 65 institutional investors held Adicet Bio (ACET) as of Q2 2021, up from 53 in Q1 2021.
- Funds reported $218M of Adicet Bio stock for Q2 2021, down 18% quarter-over-quarter.
- 20 funds opened new Adicet Bio positions in Q2 2021 and 8 closed out, a net change of +12 holders.
- The largest Adicet Bio buyer in Q2 2021 was BlackRock, an estimated $9.49M added.
- The largest Adicet Bio seller in Q2 2021 was VR Adviser, an estimated $10.4M sold.
Based on aggregated 13F filings for Q2 2021.